Apalutamide
- TRADE NAME: Erleada (Janssen Biotech)
- INDICATIONS: Non-metastatic castration-resistant prostate cancer
- CLASS: Androgen antagonist
FDA APPROVAL DATE: 02/14/2018
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
Can cause fetal harm and potential loss of pregnancy
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 01/29/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric